Effect of lipoic acid combination with valsartan on diabetic nephropathy and associated adverse reactions

Abstract

Purpose: To investigate the effect of lipoic acid combination with valsartan on diabetic nephropathy (DN) and its associated adverse  reactions. Methods: A retrospective analysis was conducted on 120 patients who treated for DN at the Second Affiliated Hospital of Shenzhen  University, China between August 2019 and October 2022. Based on different treatment approaches, control group comprised 55 patients  receiving valsartan alone, while joint group consisted of 65 patients receiving a combination of valsartan and lipoic acid.  Therapeutic effectiveness and adverse events were compared between the groups. Additionally, changes in blood glucose and renal  function parameters were evaluated pre- and post-treatment. Results: Post-treatment, both groups exhibited improvements in blood  glucose and renal function parameters compared to pre-treatment values (p < 0.05). However, joint group demonstrated superior improvements in these parameters compared to control group (p < 0.05). Total efficacy was significantly higher in the joint group than in  control group (p < 0.05). No significant differences were observed between the groups' incidence of adverse reactions (p > 0.05).   Conclusion: Concurrent therapy of lipoic acid and valsartan sly treats DN. It enhances the regulation of blood glucose levels and  improves renal function with high safety. Further studies employing larger sample sizes and prospective designs with comprehensive  patient follow-up are required to further validate and enhance the reliability of these findings.